Identification

Name
Isocarboxazid
Accession Number
DB01247  (APRD00701)
Type
Small Molecule
Groups
Approved
Description

An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)

Structure
Thumb
Synonyms
  • Isocarboxazida
  • Isocarboxazide
  • Isocarboxazidum
External IDs
RO 5-0831 / RO-5-0831
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MarplanTablet10 mg/1OralValidus Pharmaceuticals1959-07-01Not applicableUs
International/Other Brands
Enerzer (Takeda) / Isocarboxazid (Alliance) / Marplan
Categories
UNII
34237V843T
CAS number
59-63-2
Weight
Average: 231.2505
Monoisotopic: 231.100776675
Chemical Formula
C12H13N3O2
InChI Key
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
IUPAC Name
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
SMILES
CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1

Pharmacology

Indication

May be used to treat major depressive disorder.

Structured Indications
Pharmacodynamics

Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression.

Mechanism of action

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
AAmine oxidase [flavin-containing] B
inhibitor
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic and rapid (by oxidation).

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineIsocarboxazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineIsocarboxazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineIsocarboxazid may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseIsocarboxazid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololIsocarboxazid may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acetophenazine.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Isocarboxazid.Experimental
AlbiglutideIsocarboxazid may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aldesleukin.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Isocarboxazid.Approved, Illicit
AliskirenIsocarboxazid may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Isocarboxazid.Approved, Investigational
AlogliptinIsocarboxazid may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Isocarboxazid.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Isocarboxazid.Illicit
AlprenololIsocarboxazid may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Isocarboxazid.Approved
AmbrisentanIsocarboxazid may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Isocarboxazid.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amiloride.Approved
AmineptineIsocarboxazid may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isocarboxazid.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isocarboxazid.Approved
AmlodipineIsocarboxazid may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Illicit
AmperozideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amperozide.Experimental
AmphetamineIsocarboxazid may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isocarboxazid.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Isocarboxazid.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Isocarboxazid.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isocarboxazid.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isocarboxazid.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Asenapine.Approved
AtenololIsocarboxazid may increase the hypotensive activities of Atenolol.Approved
AtomoxetineIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineIsocarboxazid may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Azaperone.Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Azilsartan medoxomil.Approved
BambuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Isocarboxazid.Experimental
BarbitalBarbital may increase the hypotensive activities of Isocarboxazid.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isocarboxazid.Approved
BenazeprilIsocarboxazid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIsocarboxazid may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinIsocarboxazid may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Benperidol.Investigational
BenzphetamineIsocarboxazid may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilIsocarboxazid may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Isocarboxazid.Approved
BetaxololIsocarboxazid may increase the hypotensive activities of Betaxolol.Approved
BethanidineIsocarboxazid may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bezafibrate.Approved
BietaserpineIsocarboxazid may increase the hypotensive activities of Bietaserpine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bifeprunox.Investigational
BimatoprostIsocarboxazid may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIsocarboxazid may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Isocarboxazid.Approved, Investigational
BosentanIsocarboxazid may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Isocarboxazid may increase the hypotensive activities of BQ-123.Investigational
BretyliumIsocarboxazid may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.Approved
BrofaromineIsocarboxazid may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isocarboxazid.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bromperidol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isocarboxazid.Approved, Investigational
BupranololIsocarboxazid may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isocarboxazid.Approved, Illicit, Investigational, Vet Approved
BupropionIsocarboxazid may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Isocarboxazid.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isocarboxazid.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Isocarboxazid.Approved
CadralazineIsocarboxazid may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIsocarboxazid may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanIsocarboxazid may increase the hypotensive activities of Candesartan.Approved
CandoxatrilIsocarboxazid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIsocarboxazid may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isocarboxazid.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Isocarboxazid.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cariprazine.Approved
CaroxazoneIsocarboxazid may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololIsocarboxazid may increase the hypotensive activities of Carteolol.Approved
CarvedilolIsocarboxazid may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololIsocarboxazid may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideIsocarboxazid may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineIsocarboxazid may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneIsocarboxazid may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIsocarboxazid may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIsocarboxazid may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isocarboxazid.Approved
CirazolineIsocarboxazid may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Isocarboxazid.Approved
ClemastineIsocarboxazid may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Isocarboxazid.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isocarboxazid.Approved, Vet Approved
ClonidineIsocarboxazid may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clopenthixol.Experimental
CloranololIsocarboxazid may increase the hypotensive activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Isocarboxazid.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isocarboxazid.Approved, Investigational
CryptenamineIsocarboxazid may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.Approved
CyclopenthiazideIsocarboxazid may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIsocarboxazid may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineIsocarboxazid may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinIsocarboxazid may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.Investigational
DebrisoquinIsocarboxazid may increase the hypotensive activities of Debrisoquin.Approved
DelaprilIsocarboxazid may increase the hypotensive activities of Delapril.Experimental
DeserpidineIsocarboxazid may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Isocarboxazid.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isocarboxazid.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateIsocarboxazid may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineIsocarboxazid may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanIsocarboxazid may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Isocarboxazid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isocarboxazid.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Isocarboxazid.Approved
DiazoxideIsocarboxazid may increase the hypotensive activities of Diazoxide.Approved
DibenzepinIsocarboxazid may increase the serotonergic activities of Dibenzepin.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Diclofenamide.Approved
diethylnorspermineIsocarboxazid may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionIsocarboxazid may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineIsocarboxazid may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isocarboxazid.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isocarboxazid.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Isocarboxazid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isocarboxazid.Experimental, Illicit
DiltiazemIsocarboxazid may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Isocarboxazid.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dipyridamole.Approved
DisopyramideIsocarboxazid may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Isocarboxazid.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideIsocarboxazid may increase the hypotensive activities of Dorzolamide.Approved
DosulepinIsocarboxazid may increase the serotonergic activities of Dosulepin.Approved
DoxapramIsocarboxazid may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinIsocarboxazid may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Isocarboxazid.Approved
DoxylamineIsocarboxazid may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Isocarboxazid.Investigational
DroperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Isocarboxazid.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droxidopa.Approved, Investigational
DulaglutideIsocarboxazid may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineIsocarboxazid may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Isocarboxazid.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ecopipam.Investigational
EfonidipineIsocarboxazid may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Isocarboxazid.Approved, Investigational
EmpagliflozinIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilIsocarboxazid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIsocarboxazid may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIsocarboxazid may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Isocarboxazid.Approved, Investigational
EpanololIsocarboxazid may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EplerenoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Eplerenone.Approved
EpoprostenolIsocarboxazid may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIsocarboxazid may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Isocarboxazid.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Isocarboxazid.Approved, Investigational
EsmirtazapineIsocarboxazid may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Isocarboxazid.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Isocarboxazid.Approved, Illicit
EtoperidoneIsocarboxazid may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Isocarboxazid.Illicit, Vet Approved
ExenatideIsocarboxazid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineIsocarboxazid may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamIsocarboxazid may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isocarboxazid.Approved, Illicit, Investigational, Vet Approved
Ferulic acidIsocarboxazid may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isocarboxazid.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluanisone.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Isocarboxazid.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluspirilene.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Isocarboxazid.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Formoterol.Approved, Investigational
FosinoprilIsocarboxazid may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Isocarboxazid.Approved, Investigational
FurazolidoneIsocarboxazid may increase the hypertensive activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Furosemide.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Isocarboxazid.Experimental
GliclazideIsocarboxazid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIsocarboxazid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIsocarboxazid may increase the hypoglycemic activities of Glipizide.Approved
GlyburideIsocarboxazid may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
GuanabenzIsocarboxazid may increase the hypotensive activities of Guanabenz.Approved
GuanadrelIsocarboxazid may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIsocarboxazid may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIsocarboxazid may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIsocarboxazid may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorIsocarboxazid may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIsocarboxazid may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIsocarboxazid may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Isocarboxazid.Approved, Vet Approved
HarmalineIsocarboxazid may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Isocarboxazid.Approved, Illicit
HexamethoniumIsocarboxazid may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Isocarboxazid.Approved
HydracarbazineIsocarboxazid may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineIsocarboxazid may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideIsocarboxazid may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineIsocarboxazid may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Isocarboxazid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Isocarboxazid.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isocarboxazid.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.Approved
IndalpineIsocarboxazid may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIsocarboxazid may increase the hypotensive activities of Indapamide.Approved
IndenololIsocarboxazid may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIsocarboxazid may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartIsocarboxazid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIsocarboxazid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIsocarboxazid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIsocarboxazid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIsocarboxazid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIsocarboxazid may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Isocarboxazid.Approved
IprindoleIsocarboxazid may increase the serotonergic activities of Iprindole.Experimental
IproclozideIsocarboxazid may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIsocarboxazid may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanIsocarboxazid may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsoetarineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoflurane.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsocarboxazid may increase the hypotensive activities of Isradipine.Approved
KetanserinIsocarboxazid may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Isocarboxazid.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Isocarboxazid.Approved, Nutraceutical, Withdrawn
LabetalolIsocarboxazid may increase the hypotensive activities of Labetalol.Approved
LacidipineIsocarboxazid may increase the hypotensive activities of Lacidipine.Approved
LatanoprostIsocarboxazid may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIsocarboxazid may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levobupivacaine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Isocarboxazid.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Isocarboxazid.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levomilnacipran.Approved
LevonordefrinIsocarboxazid may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Isocarboxazid.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levosimendan.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Linezolid.Approved, Investigational
LinsidomineIsocarboxazid may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideIsocarboxazid may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineIsocarboxazid may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilIsocarboxazid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Isocarboxazid.Approved
LithiumThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Isocarboxazid.Illicit
LofepramineIsocarboxazid may increase the serotonergic activities of Lofepramine.Experimental
LofexidineIsocarboxazid may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lorcaserin.Approved
LosartanIsocarboxazid may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.Approved
MacitentanIsocarboxazid may increase the hypotensive activities of Macitentan.Approved
ManidipineIsocarboxazid may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.Approved
MebanazineIsocarboxazid may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineIsocarboxazid may increase the hypotensive activities of Mecamylamine.Approved
MecaserminIsocarboxazid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Melperone.Approved
MephedroneIsocarboxazid may increase the hypertensive activities of Mephedrone.Investigational
MephentermineIsocarboxazid may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Isocarboxazid.Experimental
MequitazineIsocarboxazid may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mesoridazine.Approved
MetaraminolIsocarboxazid may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminIsocarboxazid may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Isocarboxazid.Approved, Illicit
MethamphetamineIsocarboxazid may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isocarboxazid.Approved
MethoserpidineIsocarboxazid may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methotrimeprazine.Approved
MethoxamineIsocarboxazid may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Isocarboxazid.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Isocarboxazid.Experimental
Methylene blueIsocarboxazid may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateIsocarboxazid may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isocarboxazid.Approved
MetipranololIsocarboxazid may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.Approved, Investigational
MetolazoneIsocarboxazid may increase the hypotensive activities of Metolazone.Approved
MetoprololIsocarboxazid may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIsocarboxazid may increase the hypotensive activities of Metyrosine.Approved
MianserinIsocarboxazid may increase the neurotoxic activities of Mianserin.Approved
MibefradilIsocarboxazid may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineIsocarboxazid may increase the hypertensive activities of Midodrine.Approved
MidomafetamineIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MifepristoneIsocarboxazid may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIsocarboxazid may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Isocarboxazid.Approved
MinoxidilIsocarboxazid may increase the hypotensive activities of Minoxidil.Approved
MirtazapineIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAIsocarboxazid may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.Approved
MoexiprilIsocarboxazid may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mosapramine.Experimental
MoxonidineIsocarboxazid may increase the hypotensive activities of Moxonidine.Approved
MuzolimineIsocarboxazid may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nabilone.Approved, Investigational
NadololIsocarboxazid may increase the hypotensive activities of Nadolol.Approved
NaftopidilIsocarboxazid may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Isocarboxazid.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Isocarboxazid.Approved, Investigational
NateglinideIsocarboxazid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololIsocarboxazid may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Isocarboxazid.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nesiritide.Approved, Investigational
NialamideIsocarboxazid may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineIsocarboxazid may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Isocarboxazid.Approved
NifedipineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nifedipine.Approved
NiguldipineIsocarboxazid may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIsocarboxazid may increase the hypotensive activities of Nilvadipine.Approved
NimodipineIsocarboxazid may increase the hypotensive activities of Nimodipine.Approved
NisoldipineIsocarboxazid may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIsocarboxazid may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitroglycerin.Approved, Investigational
NitroprussideIsocarboxazid may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineIsocarboxazid may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Isocarboxazid.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isocarboxazid.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Obinutuzumab.Approved
OctamoxinIsocarboxazid may increase the hypertensive activities of Octamoxin.Withdrawn
OlmesartanIsocarboxazid may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olodaterol.Approved
OmapatrilatIsocarboxazid may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Isocarboxazid.Approved
OpipramolIsocarboxazid may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Isocarboxazid.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Osanetant.Investigational
OxprenololIsocarboxazid may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Papaverine.Approved
PargylineIsocarboxazid may increase the hypotensive activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Isocarboxazid.Approved, Investigational
PenbutololIsocarboxazid may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Penfluridol.Experimental
PentamidineIsocarboxazid may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isocarboxazid.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
PentoliniumIsocarboxazid may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Isocarboxazid.Approved, Vet Approved, Withdrawn
PerindoprilIsocarboxazid may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perphenazine.Approved
PethidineIsocarboxazid may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Isocarboxazid.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isocarboxazid.Approved
PheniprazineIsocarboxazid may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Isocarboxazid.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Isocarboxazid.Experimental
PhenoxybenzamineIsocarboxazid may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineIsocarboxazid may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineIsocarboxazid may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineIsocarboxazid may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIsocarboxazid may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Isocarboxazid.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Isocarboxazid.Investigational
PimozideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pimozide.Approved
PinacidilIsocarboxazid may increase the hypotensive activities of Pinacidil.Withdrawn
PindololIsocarboxazid may increase the hypotensive activities of Pindolol.Approved
PioglitazoneIsocarboxazid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Isocarboxazid.Investigational
PirlindoleIsocarboxazid may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineIsocarboxazid may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenIsocarboxazid may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideIsocarboxazid may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pramipexole.Approved, Investigational
PramlintideIsocarboxazid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinIsocarboxazid may increase the hypotensive activities of Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Isocarboxazid.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Isocarboxazid.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propofol.Approved, Investigational, Vet Approved
PropranololIsocarboxazid may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isocarboxazid.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Isocarboxazid.Investigational
PseudoephedrineIsocarboxazid may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Quetiapine.Approved
QuinaprilIsocarboxazid may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineIsocarboxazid may increase the hypoglycemic activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Raclopride.Investigational
RamiprilIsocarboxazid may increase the hypotensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remifentanil.Approved
RemikirenIsocarboxazid may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride.Approved, Withdrawn
RepaglinideIsocarboxazid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineIsocarboxazid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Reserpine.Approved
RilmenidineIsocarboxazid may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatIsocarboxazid may increase the hypotensive activities of Riociguat.Approved
RisperidoneIsocarboxazid may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritanserin.Investigational
RitobegronIsocarboxazid may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Isocarboxazid.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropivacaine.Approved
RosiglitazoneIsocarboxazid may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sacubitril.Approved
SafrazineIsocarboxazid may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salmeterol.Approved
SaprisartanIsocarboxazid may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinIsocarboxazid may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isocarboxazid.Approved, Investigational, Vet Approved
SelexipagIsocarboxazid may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Isocarboxazid.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sevoflurane.Approved, Vet Approved
SitagliptinIsocarboxazid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanIsocarboxazid may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sotalol.Approved
SpiraprilIsocarboxazid may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sufentanil.Approved, Investigational
SulfadiazineIsocarboxazid may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Isocarboxazid.Approved, Investigational
SunitinibIsocarboxazid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololIsocarboxazid may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Isocarboxazid.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Isocarboxazid.Approved
TelmisartanIsocarboxazid may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIsocarboxazid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.Approved
TerlipressinIsocarboxazid may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Isocarboxazid.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Isocarboxazid.Approved
TetrahydropalmatineIsocarboxazid may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineIsocarboxazid may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineIsocarboxazid may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioridazine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Isocarboxazid.Approved
TiaprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tiapride.Approved, Investigational
TiboloneIsocarboxazid may increase the hypotensive activities of Tibolone.Approved
TicrynafenIsocarboxazid may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Isocarboxazid.Experimental
TimololIsocarboxazid may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tizanidine.Approved
TolazamideIsocarboxazid may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineIsocarboxazid may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideIsocarboxazid may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.Approved, Withdrawn
TolonidineIsocarboxazid may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneIsocarboxazid may increase the hypertensive activities of Toloxatone.Approved
TorasemideIsocarboxazid may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Isocarboxazid.Approved, Investigational
TrandolaprilIsocarboxazid may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineIsocarboxazid may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isocarboxazid.Approved
TravoprostIsocarboxazid may increase the hypotensive activities of Travoprost.Approved
TreprostinilIsocarboxazid may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triamterene.Approved
TrichlormethiazideIsocarboxazid may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triflupromazine.Approved, Vet Approved
TrimazosinIsocarboxazid may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIsocarboxazid may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isocarboxazid.Approved
TropisetronTropisetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
UnoprostoneIsocarboxazid may increase the hypotensive activities of Unoprostone.Approved
UrapidilIsocarboxazid may increase the hypotensive activities of Urapidil.Investigational
ValsartanIsocarboxazid may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Isocarboxazid.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vilazodone.Approved
VincamineIsocarboxazid may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIsocarboxazid may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vortioxetine.Approved
XipamideIsocarboxazid may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIsocarboxazid may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineIsocarboxazid may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.Approved
ZofenoprilIsocarboxazid may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Isocarboxazid.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals, avoid tyramine, caffeine and alcohol.

References

Synthesis Reference

U.S. Patent 2,908,688.

General References
  1. Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE: A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 1988 Dec;8(6):391-6. [PubMed:3069879 ]
External Links
Human Metabolome Database
HMDB15377
KEGG Drug
D02580
PubChem Compound
3759
PubChem Substance
46505330
ChemSpider
3628
BindingDB
163692
ChEBI
93635
ChEMBL
CHEMBL1201168
Therapeutic Targets Database
DAP000577
PharmGKB
PA450101
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Isocarboxazid
ATC Codes
N06AF01 — Isocarboxazid
AHFS Codes
Not Available
PDB Entries
FDA label
Download (56.5 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAlzheimer's Disease (AD) / Healthy Volunteers / Molecular Imaging1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Marplan 10 mg tablet3.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105-106 °CU.S. Patent 2,908,688.
water solubility1.6 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP1.49HANSCH,C ET AL. (1995)
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.19ALOGPS
logP1.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.02ChemAxon
pKa (Strongest Basic)3.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.78 m3·mol-1ChemAxon
Polarizability24.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9783
Caco-2 permeable-0.5531
P-glycoprotein substrateNon-substrate0.6987
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9716
Renal organic cation transporterNon-inhibitor0.8247
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.8141
CYP450 3A4 substrateNon-substrate0.6057
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8885
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8518
Ames testAMES toxic0.5973
CarcinogenicityCarcinogens 0.5
BiodegradationNot ready biodegradable0.9227
Rat acute toxicity2.9486 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9209
hERG inhibition (predictor II)Non-inhibitor0.9069
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9600000000-952a7c1093fe532d1df3
Mass Spectrum (Electron Ionization)MSsplash10-0006-9500000000-6ab30f52fc69889b3fa2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-9210100010-78b2f412502a142509e6

Taxonomy

Description
This compound belongs to the class of chemical entities known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Isoxazoles / Heteroaromatic compounds / Carboxylic acid hydrazides / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Azole / Isoxazole / Heteroaromatic compound / Carboxylic acid hydrazide / Carboxylic acid derivative / Organoheterocyclic compound / Azacycle / Oxacycle / Organooxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. [PubMed:7612154 ]
  3. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Mason ST: Chronic administration of type A monoamine oxidase inhibitors increases duration of thiopentone anaesthesia in the rat. Physiol Behav. 1985 Aug;35(2):201-3. [PubMed:4070383 ]
  2. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:56